Table 1 Characteristics of the 58 STS patients treated with pazopanib
Characteristics | No. | Percentage |
|---|---|---|
Age | ||
Median | 52 | |
Range | 19–72 | |
≥ 60 year | 19 | 33 |
Gender | ||
Male | 28 | 48 |
Female | 30 | 52 |
ECOG performance status | ||
0 | 35 | 60 |
1 | 23 | 40 |
2 or more | 0 | 0 |
Smoking history | ||
Absent | 38 | 66 |
Present | 20 | 34 |
Smoking index | ||
Median | 238 | |
Range | 64–1170 | |
≥ 400 | 6 | 10 |
Hypertension | ||
Absent | 48 | 83 |
Present | 10 | 17 |
Pathological diagnoses | ||
Leiomyosarcoma | 13 | 22 |
Synovial sarcoma | 9 | 16 |
Liposarcoma | 9 | 16 |
Other histologies | 27 | 46 |
Primary site of disease | ||
Extremities | 21 | 36 |
Non-extremities | 37 | 64 |
Pulmonary disease | ||
Lung lesions present | 41 | 71 |
Pleural lesions present | 23 | 40 |
Number of lung lesions | ||
1 | 6 | 10 |
2–5 | 16 | 28 |
6–9 | 6 | 10 |
> 10 | 13 | 22 |
Maximum diameter of lung lesions | ||
< 10 mm | 2 | 3 |
10–20 mm | 11 | 19 |
20–30 mm | 7 | 12 |
30–50 mm | 8 | 14 |
> 50 mm | 13 | 22 |